financetom
Business
financetom
/
Business
/
Sealed Air to See Soft Volumes, High Debt, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sealed Air to See Soft Volumes, High Debt, RBC Says
Jul 19, 2024 9:47 AM

12:25 PM EDT, 07/19/2024 (MT Newswires) -- Sealed Air ( SEE ) is expected to see weak sales volume, with prices and costs remaining steady or slightly declining, and significant debt, RBC Capital Markets said in a note sent Friday.

Analysts, including Arun Viswanathan, said they are revising down their estimated earnings before interest, taxes, depreciation, and amortization, or EBITDA, for 2024 and 2025 to $1.10 billion and $1.15 billion respectively, from $1.10 billion and $1.16 billion.

Sealed Air ( SEE ) might see easier year-over-year comparisons in its Protective segment in H2 2024. But, it is yet to see a positive increase in actual demand and has potential challenges ahead such as major customers shifting away from the company's traditional Bubble-Wrap and Instapak products. New products like fiber-based mailers in Protective and compostable trays in Food are unlikely to significantly boost sales or EBITDA in 2024.

"While Sealed Air ( SEE ) has guided relatively conservatively for 2024, new first-time Chief Executive Patrick Kivits could reset expectations even lower to establish a base from which Sealed Air ( SEE ) could beat and raise," the analysts said.

The analysts added that weak sales volume might lead to increased working capital needs, while key investments in new products are expected to keep capital expenditures around $240 million. Sealed Air ( SEE ) might only achieve its target of $325 million to $425 million in free cash flow for 2024 under the best circumstances.

RBC downgraded Sealed Air ( SEE ) to sector perform from outperform and cut its price target to $40 from $43.

Price: 35.70, Change: -0.69, Percent Change: -1.90

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Genetic medicines firm MeiraGTx misses Q3 revenue expectations, net loss widens
Genetic medicines firm MeiraGTx misses Q3 revenue expectations, net loss widens
Nov 13, 2025
Overview * MeiraGTx ( MGTX ) Q3 revenue misses analyst expectations, declining significantly from last year * Company enters strategic collaboration with Eli Lilly, including $75 mln upfront payment * Net loss widens to $50.5 mln in Q3, driven by increased R&D expenses Outlook * Company anticipates Phase 2 data for AAV-hAQP1 in early 2027 * MeiraGTx ( MGTX )...
DiamondRock Hospitality to Transfer Listing to Nasdaq From NYSE
DiamondRock Hospitality to Transfer Listing to Nasdaq From NYSE
Nov 13, 2025
08:14 AM EST, 11/13/2025 (MT Newswires) -- DiamondRock Hospitality ( DRH ) said Thursday it will voluntarily transfer its class A common shares listing to Nasdaq from the New York Stock Exchange. The company said it anticipates its common shares to start trading on the Nasdaq Global Select Market on Dec. 1, under the current DRH ticker. ...
Nortech Systems Q3 net loss narrows due to restructuring efforts 
Nortech Systems Q3 net loss narrows due to restructuring efforts 
Nov 13, 2025
Overview * Nortech Q3 2025 net sales decline 2.9% yr/yr to $30.5 mln * Net loss narrows to $146,000 in Q3 2025 from $739,000 in Q3 2024 * Adjusted EBITDA rises to $1.3 mln in Q3 2025 from $0.1 mln in Q3 2024 Outlook * Company highlights AS9100:D certification at Monterrey facility enhancing aerospace offerings * Nortech ( NSYS )...
Biopharma firm Clene reports Q3 net loss of $8.8 mln
Biopharma firm Clene reports Q3 net loss of $8.8 mln
Nov 13, 2025
Overview * Clene ( CLNN ) reports Q3 net loss of $8.8 mln, increased from $8.0 mln last year * Cash and cash equivalents total $7.9 mln, runway extended into Q2 2026 * Company plans NDA submission for CNM-Au8 in Q1 2026 under accelerated approval Outlook * Clene plans to submit NDA for ALS treatment in Q1 2026 * Company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved